Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Tandem Diabetes Care Inc

Healthcare US TNDM

16.6USD
0.80(5.06%)

Last update at 2026-06-12T20:00:00Z

Day Range

15.5116.64
LowHigh

52 Week Range

15.7553.69
LowHigh

Fundamentals

  • Previous Close 15.80
  • Market Cap1537.29M
  • Volume1768107
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-75.06800M
  • Revenue TTM982.95M
  • Revenue Per Share TTM14.96
  • Gross Profit TTM 513.31M
  • Diluted EPS TTM-2.79

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -92.85200M 15.90M -36.28200M -24.60400M -122.56000M
Minority interest - - - - -
Net income -94.59400M 15.57M -34.38200M -24.75300M -122.61100M
Selling general administrative 335.68M 261.51M 204.90M 165.74M 105.23M
Selling and marketing expenses - - - - -
Gross profit 412.99M 376.21M 260.52M 194.21M 89.82M
Reconciled depreciation 14.33M 13.85M 10.45M 6.07M 5.82M
Ebit -61.80900M 8.81M -18.40800M -22.79400M -50.45200M
Ebitda -30.77000M 22.65M -7.95700M -16.72200M -44.63100M
Depreciation and amortization 31.04M 13.85M 10.45M 6.07M 5.82M
Non operating income net other -0.00400M -6.75200M -28.32500M -7.88200M -77.92900M
Operating income -61.80900M 8.81M -7.95700M -16.72200M -44.63100M
Other operating expenses 863.03M 680.15M 506.79M 379.03M 228.50M
Interest expense 4.31M 4.31M 12.15M 0.08M 7.58M
Tax provision 1.74M 0.34M -1.90000M 0.15M 0.05M
Interest income 6.06M 0.67M 1.57M 3.27M 1.46M
Net interest income -0.15200M -5.36600M -11.23800M 3.19M -6.12200M
Extraordinary items - - - - -
Non recurring 31.04M - - - -
Other items - - - - -
Income tax expense 1.74M 0.34M -1.90000M 0.15M 0.05M
Total revenue 801.22M 702.80M 498.83M 362.31M 183.87M
Total operating expenses 474.80M 353.56M 268.48M 210.93M 134.45M
Cost of revenue 388.23M 326.58M 238.31M 168.09M 94.04M
Total other income expense net -31.04300M 7.09M -28.32500M -7.88200M -77.92900M
Discontinued operations - - - - -
Net income from continuing ops -94.59400M 15.57M -34.38200M -24.75300M -122.61100M
Net income applicable to common shares -94.59400M 15.57M -34.38200M -24.75300M -122.61100M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 967.66M 952.66M 1052.79M 905.14M 716.41M
Intangible assets 0.93M 2.78M 4.63M 6.64M 8.80M
Earning assets - - - - -
Other current assets 21.96M 16.59M 7.24M 8.43M 6.38M
Total liab 704.56M 639.03M 612.84M 472.02M 350.11M
Total stockholder equity 263.10M 313.63M 439.95M 433.11M 366.31M
Deferred long term liab - - - - -
Other current liab 149.82M 84.62M 77.60M 84.36M 70.54M
Common stock 0.07M 0.07M 0.07M 0.06M 0.06M
Capital stock 0.07M 0.07M 0.07M 0.06M 0.06M
Retained earnings -1047.82500M -951.80000M -729.18900M -634.59500M -659.21000M
Other liab - - 36.09M 34.78M 27.36M
Good will - - - - -
Other assets - - 10.70M 9.09M 29.16M
Cash 69.23M 58.87M 172.52M 71.18M 94.61M
Cash and equivalents - - - - -
Total current liabilities 247.05M 195.26M 165.29M 131.86M 103.85M
Current deferred revenue 11.83M 43.99M 18.84M 10.18M 6.08M
Net debt 404.33M 356.80M 247.36M 243.49M 133.71M
Short term debt 40.67M 17.06M 13.12M 9.28M 9.42M
Short long term debt 40.67M - - - -
Short long term debt total 473.56M 415.67M 419.88M 314.67M 228.32M
Other stockholder equity 1312.80M 1264.00M 1170.89M 1068.26M 1025.23M
Property plant equipment - - 68.55M 50.39M 50.02M
Total current assets 724.49M 747.99M 849.98M 811.52M 637.24M
Long term investments 74.55M - - - -
Net tangible assets - - 439.95M 433.11M 366.31M
Short term investments 369.10M 409.04M 444.38M 552.63M 390.32M
Net receivables 114.58M 105.56M 114.72M 110.72M 82.19M
Long term debt 308.27M 285.04M 283.23M 281.47M 202.98M
Inventory 149.61M 157.94M 111.12M 68.55M 63.72M
Accounts payable 44.73M 49.59M 55.73M 28.03M 17.80M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.94700M 1.37M -1.81700M -0.61600M 0.22M
Additional paid in capital - - - - -
Common stock total equity - - 0.07M 0.06M 14.26M
Preferred stock total equity - - - - -
Retained earnings total equity - - -729.18900M -634.59500M -659.21000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.24M 37.56M 19.00M 9.09M 0.58M
Deferred long term asset charges - - - - -
Non current assets total 243.17M 204.67M 202.81M 93.62M 79.18M
Capital lease obligations 124.63M 130.63M 136.65M 33.20M 25.34M
Long term debt total - - - 281.47M 202.98M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 33.17M -163.36500M -263.76200M -37.41400M -87.75300M
Change to liabilities 13.10M 33.73M 12.88M 28.90M 17.87M
Total cashflows from investing activities 33.17M -186.87600M -296.05600M -56.95500M -90.73900M
Net borrowings - - 278.69M 278.69M -87.71100M
Total cash from financing activities 16.88M 51.93M 314.44M 24.21M 117.18M
Change to operating activities 12.78M 29.42M 9.46M 18.82M 13.84M
Net income -94.59400M 15.57M -34.38200M -24.75300M -122.61100M
Change in cash 101.34M -23.43200M 43.44M 9.35M 18.13M
Begin period cash flow 71.18M 94.61M 51.17M 41.83M 23.70M
End period cash flow 172.52M 71.18M 94.61M 51.17M 41.83M
Total cash from operating activities 50.46M 111.36M 24.67M 41.91M -8.31900M
Issuance of capital stock - - 0.00000M 0.00000M 172.93M
Depreciation 14.33M 13.85M 10.45M 6.07M 5.82M
Other cashflows from investing activities -34.57500M -9.33100M -4.88600M -37.41400M -87.75300M
Dividends paid - - - - -
Change to inventory -42.45200M -4.95400M -15.36100M -30.97500M 6.76M
Change to account receivables -7.83000M -30.98000M -38.83700M -13.69800M -15.84800M
Sale purchase of stock 17.55M 51.93M 69.82M 24.21M 31.97M
Other cashflows from financing activities -0.59200M 0.59M 247.57M 0.33M 31.97M
Change to netincome 121.73M 65.48M 76.39M 73.50M 97.75M
Capital expenditures 42.95M 23.51M 32.29M 19.54M 2.99M
Change receivables -7.83000M -30.98000M -38.83700M -13.69800M -15.84800M
Cash flows other operating 40.10M 16.57M 4.73M 3.42M -0.31300M
Exchange rate changes - - - - -
Cash and cash equivalents changes 100.51M -23.58500M 43.05M 9.16M 18.13M
Change in working capital -4.64900M 14.37M -36.58900M -12.34900M 8.46M
Stock based compensation 84.92M 60.75M 58.43M 58.07M 23.74M
Other non cash items 50.46M 2.27M 28.88M -0.32100M 76.27M
Free cash flow 7.51M 87.85M -7.62500M 22.36M -11.30500M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TNDM
Tandem Diabetes Care Inc		 0.80 5.06% 16.60 - 1111.11 1.56 9.90 1.69 -10.7153
ABT
Abbott Laboratories		 -1.47 1.64% 88.18 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 6.56 2.15% 312.20 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.13 0.16% 80.20 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.26 0.55% 46.91 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Tandem Diabetes Care Inc

12400 High Bluff Drive, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Mr. John F. Sheridan Pres, CEO & Director 1955
Ms. Leigh A. Vosseller Exec. VP, CFO & Treasurer 1973
Mr. David B. Berger Esq. Exec. VP & COO 1970
Ms. Susan M. Morrison Exec. VP & Chief Admin. Officer 1979
Mr. Brian B. Hansen Exec. VP & Chief Commercial Officer 1968
Ms. Elizabeth Anne Gasser Exec. VP & Chief Strategy Officer 1976
Mr. Rick A. Carpenter Chief Technical Officer 1963
Ms. Shannon M. Hansen Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1966
Mr. Ross Sylvia VP of Marketing NA
Mr. Tom Fox Sr. VP of HR & Organizational Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.